Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nature deficit disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    33 result(s) found for: Nature deficit disorder. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-002221-21 Sponsor Protocol Number: SPD503-312 Start Date*: 2011-08-30
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once daily Dosing with Extended-release Guanfacin...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.0 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.0 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.0 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006441-14 Sponsor Protocol Number: CRIT124DDE04 Start Date*: 2007-04-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, rater-blinded cross-over multicenter study comparing the clinical efficacy of Ritalin® LA (methylphenidate) treatment (20 or 40 mg orally o.d.) in children with ADHD under different b...
    Medical condition: attention deficit hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000227-25 Sponsor Protocol Number: CRIT124DDE03 Start Date*: 2008-10-15
    Sponsor Name:Dept. Child & Adolescent Psychiatrie
    Full Title: A single-center, single-blind, randomized, oral dose cross-over study in prepuberal boys with ADHD to investigate efficacy and bioequivalence of 20 mg Ritalin LA® compared to 20 mg Medikinet® retar...
    Medical condition: Patients having a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) of any type according to DSM-IV criteria, as established by history, psychiatric examination and a structured diagnost...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000679-90 Sponsor Protocol Number: SPD489-325 Start Date*: 2009-04-08
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and ...
    Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) NL (Completed) SE (Completed) BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004668-31 Sponsor Protocol Number: SPD503-318 Start Date*: 2012-03-14
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...
    Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) IE (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020951-30 Sponsor Protocol Number: SPD489-404 Start Date*: 2011-03-03
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
    Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) ES (Completed) SE (Completed) PL (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005452-34 Sponsor Protocol Number: SPD489-406 Start Date*: 2013-08-20
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, ...
    Medical condition: Attention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivity
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000720-10 Sponsor Protocol Number: SPD489-326 Start Date*: 2008-11-20
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with A...
    Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-003002-28 Sponsor Protocol Number: CRIT124DDE01 Start Date*: 2005-10-31
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg...
    Medical condition: attention deficit hyperactivity disorder
    Disease: Version SOC Term Classification Code Term Level
    M15 10064104 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005512-27 Sponsor Protocol Number: B4Z-EW-LYDY Start Date*: 2007-03-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac...
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) NO (Ongoing) IE (Completed) NL (Not Authorised) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000821-29 Sponsor Protocol Number: SPD503-401 Start Date*: 2020-11-19
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
    Medical condition: Attention-deficit/hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) PT (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-018579-12 Sponsor Protocol Number: SPD503-316 Start Date*: 2011-01-26
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.1 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.1 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Prematurely Ended) FR (Completed) ES (Completed) SE (Completed) IE (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017301-11 Sponsor Protocol Number: CSLCT-BIO-09-64 Start Date*: 2010-09-20
    Sponsor Name:CSL Behring GmbH
    Full Title: An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects with Von Willebrand Disease who Completed Clinical Studies C...
    Medical condition: Von Willebrand's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001104-23 Sponsor Protocol Number: CSLCT-BIO-07-47 Start Date*: 2009-01-22
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase II, multicentre, double-blinded, randomised, cross-over study to evaluate efficacy, safety and pharmacokinetics of Biostate® in subjects with Haemophilia A.
    Medical condition: Haemophilia A - a hereditary bleeding disorder characterised by a deficiency in the plasma protein known as coagulation Factor VIII (FVIII).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018938 Haemophilia A (Factor VIII) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-002510-50 Sponsor Protocol Number: Biostate_4001 Start Date*: 2018-03-19
    Sponsor Name:CSL Behring GmbH
    Full Title: A low-interventional Multicentre Post-Authorisation Safety Study for Voncento/Biostate/Aleviate for Routine Prophylaxis, Treatment of Bleeding Events and/or Surgery in Male Subjects with Haemophilia A
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000011915 10060612 Hemophilia A LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001410-17 Sponsor Protocol Number: IGNG-0629 Start Date*: 2007-05-31
    Sponsor Name:LFB SA
    Full Title: LONG-TERM SAFETY AND EFFICACY STUDY OF IGNG, A NEW LIQUID PREPARATION OF HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE, ADMINISTERED IN CURRENT PRACTICE TO PRIMARY IMMUNODEFICIENT PATIENTS
    Medical condition: Primary Immunodeficiency
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064859 Primary immunodeficiency syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017753-34 Sponsor Protocol Number: CSLCT-BIO-08-52 Start Date*: 2010-07-09
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects with von Willebrand Disease.
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-003305-25 Sponsor Protocol Number: CSLCT-BIO-12-83 Start Date*: 2015-07-07
    Sponsor Name:CSL Behring GmbH
    Full Title: An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand Disease
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) IE (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015112-18 Sponsor Protocol Number: CSLCT-BIO-08-53 Start Date*: 2011-11-30
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase III, Open-Label, Multicentre Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Biostate® in Paediatric Subjects with Haemophilia A.
    Medical condition: Haemophilia A
    Disease: Version SOC Term Classification Code Term Level
    15.0 10010331 - Congenital, familial and genetic disorders 10018937 Haemophilia A LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-004473-27 Sponsor Protocol Number: 401GSDIA02 Start Date*: 2021-08-25
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: A Long-Term Follow-up Study to Evaluate the Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6-Phosphatase (G6Pase) in Adults with Glycogen St...
    Medical condition: Glycogen Storage Disease Type Ia (GSDIa).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10056911 Glycogen storage disease type IA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 19:05:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA